<--- Back to Details
First PageDocument Content
Growth factors / Transcription factors / Muscular dystrophy / Myostatin / Signal transduction / MyoD / Bream / Protein kinase B / Mechanistic target of rapamycin
Date: 2016-01-06 06:21:06
Growth factors
Transcription factors
Muscular dystrophy
Myostatin
Signal transduction
MyoD
Bream
Protein kinase B
Mechanistic target of rapamycin

Muscle markers and regulatory factors in marine fish under different developmental stages and treatments

Add to Reading List

Source URL: www.archanimbreed.com

Download Document from Source Website

File Size: 85,16 KB

Share Document on Facebook

Similar Documents

Free Radical Biology and Medicine–301  Contents lists available at ScienceDirect Free Radical Biology and Medicine journal homepage: www.elsevier.com/locate/freeradbiomed

Free Radical Biology and Medicine–301 Contents lists available at ScienceDirect Free Radical Biology and Medicine journal homepage: www.elsevier.com/locate/freeradbiomed

DocID: 1rrvK - View Document

Microsoft Word - AJP Jul16 PR Yue FINAL.docx

Microsoft Word - AJP Jul16 PR Yue FINAL.docx

DocID: 1qQbV - View Document

Adaptive Medicine 3(1): 11-15, 2011 DOI: AM.2011.ABA019 11  Review

Adaptive Medicine 3(1): 11-15, 2011 DOI: AM.2011.ABA019 11 Review

DocID: 1qLH8 - View Document

Calcineurin determines toxic versus beneficial responses to α-synuclein Gabriela Caraveoa,b, Pavan K. Aulucka,c,1, Luke Whitesella, Chee Yeun Chunga, Valeriya Barua,b, Eugene V. Mosharovd, Xiaohui Yane, Manu Ben-Johnyf,

Calcineurin determines toxic versus beneficial responses to α-synuclein Gabriela Caraveoa,b, Pavan K. Aulucka,c,1, Luke Whitesella, Chee Yeun Chunga, Valeriya Barua,b, Eugene V. Mosharovd, Xiaohui Yane, Manu Ben-Johnyf,

DocID: 1qF8w - View Document

PRESS RELEASE  Genkyotex’s GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis Geneva, Switzerland, and Archamps, France, 11th November, 2015 – Genkyotex, the leading de

PRESS RELEASE Genkyotex’s GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis Geneva, Switzerland, and Archamps, France, 11th November, 2015 – Genkyotex, the leading de

DocID: 1qCta - View Document